We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · July 05, 2022

Patient-Reported Outcomes in Men With mCRPC Harboring DNA Damage Response Alterations Treated With Talazoparib

European Urology


Additional Info

European Urology
Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1
Eur Urol 2022 Jun 21;[EPub Ahead of Print], F Saad, J de Bono, P Barthélémy, T Dorff, N Mehra, G Scagliotti, A Stirling, JP Machiels, V Renard, M Maruzzo, CS Higano, H Gurney, C Healy, H Bhattacharyya, B Arondekar, A Niyazov, K Fizazi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading